A novel hydroxamate-based compound WMJ-J-09 causes head and neck squamous cell carcinoma cell death via LKB1-AMPK-p38MAPK-p63-survivin cascade

Chia Sheng Yen, Cheuk Sing Choy, Wei Jan Huang, Shiu Wen Huang, Pin Ye Lai, Meng Chieh Yu, Ching Shiue, Ya Fen Hsu, Ming Jen Hsu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Growing evidence shows that hydroxamate-based compounds exhibit broad-spectrum pharmacological properties including anti-tumor activity. However, the precise mechanisms underlying hydroxamate derivative-induced cancer cell death remain incomplete understood. In this study, we explored the anti-tumor mechanisms of a novel aliphatic hydroxamate-based compound, WMJ-J-09, in FaDu head and neck squamous cell carcinoma (HNSCC) cells. WMJ-J-09 induced G2/M cell cycle arrest and apoptosis in FaDu cells. These actions were associated with liver kinase B1 (LKB1), AMP-activated protein kinase (AMPK) and p38 mitogen-activated protein kinase (p38MAPK) activation, transcription factor p63 phosphorylation, as well as modulation of p21 and survivin. LKB1-AMPK-p38MAPK signaling blockade reduced WMJ-J-09's enhancing effects in p63 phosphorylation, p21 elevation and survivin reduction. Moreover, WMJ-J-09 caused an increase in α-tubulin acetylation and interfered with microtubule assembly. Furthermore, WMJ-J-09 suppressed the growth of subcutaneous FaDu xenografts in vivo. Taken together, WMJ-J-09-induced FaDu cell death may involve LKB1-AMPK-p38MAPK-p63-survivin signaling cascade. HDACs inhibition and disruption of microtubule assembly may also contribute to WMJ-J-09's actions in FaDu cells. This study suggests that WMJ-J-09 may be a potential lead compound and warrant the clinical development in the treatment of HNSCC.

Original languageEnglish
Article number167
Pages (from-to)1-17
Number of pages17
JournalFrontiers in Pharmacology
Volume9
Issue numberMAR
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

p38 Mitogen-Activated Protein Kinases
Cell Death
Microtubules
Liver
Phosphorylation
G2 Phase Cell Cycle Checkpoints
Neoplasms
Tubulin
Acetylation
Heterografts
Transcription Factors
Pharmacology
Apoptosis
Growth
AMP-activated protein kinase kinase
Carcinoma, squamous cell of head and neck

Keywords

  • Aliphatic hydroxamate
  • Head and neck squamous cell carcinoma (HNSCC)
  • Liver kinase B1 (LKB1)
  • P63
  • Survivin
  • survivin
  • liver kinase b1
  • p63
  • head and neck squamous
  • aliphatic hydroxamate, liver kinase B1 (LKB1), p63
  • lkb1
  • cell carcinoma
  • aliphatic hydroxamate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

A novel hydroxamate-based compound WMJ-J-09 causes head and neck squamous cell carcinoma cell death via LKB1-AMPK-p38MAPK-p63-survivin cascade. / Yen, Chia Sheng; Choy, Cheuk Sing; Huang, Wei Jan; Huang, Shiu Wen; Lai, Pin Ye; Yu, Meng Chieh; Shiue, Ching; Hsu, Ya Fen; Hsu, Ming Jen.

In: Frontiers in Pharmacology, Vol. 9, No. MAR, 167, 01.03.2018, p. 1-17.

Research output: Contribution to journalArticle

@article{600fa99fa14f4c0b949eb8925159da91,
title = "A novel hydroxamate-based compound WMJ-J-09 causes head and neck squamous cell carcinoma cell death via LKB1-AMPK-p38MAPK-p63-survivin cascade",
abstract = "Growing evidence shows that hydroxamate-based compounds exhibit broad-spectrum pharmacological properties including anti-tumor activity. However, the precise mechanisms underlying hydroxamate derivative-induced cancer cell death remain incomplete understood. In this study, we explored the anti-tumor mechanisms of a novel aliphatic hydroxamate-based compound, WMJ-J-09, in FaDu head and neck squamous cell carcinoma (HNSCC) cells. WMJ-J-09 induced G2/M cell cycle arrest and apoptosis in FaDu cells. These actions were associated with liver kinase B1 (LKB1), AMP-activated protein kinase (AMPK) and p38 mitogen-activated protein kinase (p38MAPK) activation, transcription factor p63 phosphorylation, as well as modulation of p21 and survivin. LKB1-AMPK-p38MAPK signaling blockade reduced WMJ-J-09's enhancing effects in p63 phosphorylation, p21 elevation and survivin reduction. Moreover, WMJ-J-09 caused an increase in α-tubulin acetylation and interfered with microtubule assembly. Furthermore, WMJ-J-09 suppressed the growth of subcutaneous FaDu xenografts in vivo. Taken together, WMJ-J-09-induced FaDu cell death may involve LKB1-AMPK-p38MAPK-p63-survivin signaling cascade. HDACs inhibition and disruption of microtubule assembly may also contribute to WMJ-J-09's actions in FaDu cells. This study suggests that WMJ-J-09 may be a potential lead compound and warrant the clinical development in the treatment of HNSCC.",
keywords = "Aliphatic hydroxamate, Head and neck squamous cell carcinoma (HNSCC), Liver kinase B1 (LKB1), P63, Survivin, survivin, liver kinase b1, p63, head and neck squamous, aliphatic hydroxamate, liver kinase B1 (LKB1), p63, lkb1, cell carcinoma, aliphatic hydroxamate",
author = "Yen, {Chia Sheng} and Choy, {Cheuk Sing} and Huang, {Wei Jan} and Huang, {Shiu Wen} and Lai, {Pin Ye} and Yu, {Meng Chieh} and Ching Shiue and Hsu, {Ya Fen} and Hsu, {Ming Jen}",
year = "2018",
month = "3",
day = "1",
doi = "10.3389/fphar.2018.00167",
language = "English",
volume = "9",
pages = "1--17",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - A novel hydroxamate-based compound WMJ-J-09 causes head and neck squamous cell carcinoma cell death via LKB1-AMPK-p38MAPK-p63-survivin cascade

AU - Yen, Chia Sheng

AU - Choy, Cheuk Sing

AU - Huang, Wei Jan

AU - Huang, Shiu Wen

AU - Lai, Pin Ye

AU - Yu, Meng Chieh

AU - Shiue, Ching

AU - Hsu, Ya Fen

AU - Hsu, Ming Jen

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Growing evidence shows that hydroxamate-based compounds exhibit broad-spectrum pharmacological properties including anti-tumor activity. However, the precise mechanisms underlying hydroxamate derivative-induced cancer cell death remain incomplete understood. In this study, we explored the anti-tumor mechanisms of a novel aliphatic hydroxamate-based compound, WMJ-J-09, in FaDu head and neck squamous cell carcinoma (HNSCC) cells. WMJ-J-09 induced G2/M cell cycle arrest and apoptosis in FaDu cells. These actions were associated with liver kinase B1 (LKB1), AMP-activated protein kinase (AMPK) and p38 mitogen-activated protein kinase (p38MAPK) activation, transcription factor p63 phosphorylation, as well as modulation of p21 and survivin. LKB1-AMPK-p38MAPK signaling blockade reduced WMJ-J-09's enhancing effects in p63 phosphorylation, p21 elevation and survivin reduction. Moreover, WMJ-J-09 caused an increase in α-tubulin acetylation and interfered with microtubule assembly. Furthermore, WMJ-J-09 suppressed the growth of subcutaneous FaDu xenografts in vivo. Taken together, WMJ-J-09-induced FaDu cell death may involve LKB1-AMPK-p38MAPK-p63-survivin signaling cascade. HDACs inhibition and disruption of microtubule assembly may also contribute to WMJ-J-09's actions in FaDu cells. This study suggests that WMJ-J-09 may be a potential lead compound and warrant the clinical development in the treatment of HNSCC.

AB - Growing evidence shows that hydroxamate-based compounds exhibit broad-spectrum pharmacological properties including anti-tumor activity. However, the precise mechanisms underlying hydroxamate derivative-induced cancer cell death remain incomplete understood. In this study, we explored the anti-tumor mechanisms of a novel aliphatic hydroxamate-based compound, WMJ-J-09, in FaDu head and neck squamous cell carcinoma (HNSCC) cells. WMJ-J-09 induced G2/M cell cycle arrest and apoptosis in FaDu cells. These actions were associated with liver kinase B1 (LKB1), AMP-activated protein kinase (AMPK) and p38 mitogen-activated protein kinase (p38MAPK) activation, transcription factor p63 phosphorylation, as well as modulation of p21 and survivin. LKB1-AMPK-p38MAPK signaling blockade reduced WMJ-J-09's enhancing effects in p63 phosphorylation, p21 elevation and survivin reduction. Moreover, WMJ-J-09 caused an increase in α-tubulin acetylation and interfered with microtubule assembly. Furthermore, WMJ-J-09 suppressed the growth of subcutaneous FaDu xenografts in vivo. Taken together, WMJ-J-09-induced FaDu cell death may involve LKB1-AMPK-p38MAPK-p63-survivin signaling cascade. HDACs inhibition and disruption of microtubule assembly may also contribute to WMJ-J-09's actions in FaDu cells. This study suggests that WMJ-J-09 may be a potential lead compound and warrant the clinical development in the treatment of HNSCC.

KW - Aliphatic hydroxamate

KW - Head and neck squamous cell carcinoma (HNSCC)

KW - Liver kinase B1 (LKB1)

KW - P63

KW - Survivin

KW - survivin

KW - liver kinase b1

KW - p63

KW - head and neck squamous

KW - aliphatic hydroxamate, liver kinase B1 (LKB1), p63

KW - lkb1

KW - cell carcinoma

KW - aliphatic hydroxamate

UR - http://www.scopus.com/inward/record.url?scp=85042757702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042757702&partnerID=8YFLogxK

UR - http://journal.frontiersin.org/article/10.3389/fphar.2018.00167/full

UR - http://www.mendeley.com/research/novel-hydroxamatebased-compound-wmjj09-causes-head-neck-squamous-cell-carcinoma-cell-death-via-lkb1a

U2 - 10.3389/fphar.2018.00167

DO - 10.3389/fphar.2018.00167

M3 - Article

C2 - 29545751

AN - SCOPUS:85042757702

VL - 9

SP - 1

EP - 17

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - MAR

M1 - 167

ER -